We have therefore interrogated our data on BRCA1/2 primary mutation screens in women with invasive breast cancer and our BRCA1 and BRCA2 family register service databases to address the question of breast pathology in primary screens and of the proportion of BRCA1 and BRCA2 breast cancers that are triple negative or HER2 amplified [14]. Here, BRCA2 is linked to breast carcinoma.